Moderna announced on Wednesday its combined COVID and flu vaccine will proceed to the ultimate trial phase for adults aged 50 and above this year, following promising outcomes from preliminary to mid-phase research. To secure regulatory approval by 2025, Moderna’s mRNA-1083 shot…
